
    
      The study described herein is being conducted to collect clinical data associated with
      diagnosis and treatment information to support additional, on-label claims for GEHC's
      VolumeRAD advanced application. The results of this study are intended for use in the
      submission of FDA 510(k) claims in the United States.
    
  